Recruiting NA INTERVENTIONAL 9-arm
NCT06919328
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
Absorption and Tolerability of Injectable Administration of Niagen®+, Nicotinamide Riboside Chloride, a Specialized Form of Vitamin B3, as Compared to NAD+: a Double Blinded, Randomized, Controlled Clinical Trial
Sponsor: ChromaDex, Inc.
Conditions
Healthy Aging
Updated 1 time since 2025 Last updated: Apr 7, 2025 Started: Oct 31, 2024 Primary completion: Apr 30, 2025 Completion: Jun 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06919328, this NA trial focuses on Healthy Aging and remains actively recruiting participants. Sponsored by ChromaDex, Inc., it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- ChromaDex, Inc.
- Nutraceuticals Research Institute
Data source: Nutraceuticals Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .